Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 24.07 per share at the end of the most recent trading day (a -7.46% change compared to the prior day closing price) with a volume of 1.11M shares and market capitalization of 1.59B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.

The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is -84.14%, while year-to-date (YTD) performance is 73.41%. BHVN stock has a five-year performance of -38.71%. Its 52-week range is between 5.54 and 27.4, which gives BHVN stock a 52-week price range ratio of 80.88%

Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 9.81, a price-to-sale (PS) ratio of 14.96, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -310.41%, a ROC of -420.15% and a ROE of -420.15%. The company’s profit margin is -77.63%, its EBITDA margin is -84.40%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.32 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is 08th Nov 2023.

The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Strong Buy (1), with a target price of $24, which is +3.36% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biohaven Pharmaceutical Holding Company Ltd. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.29, ATR14 : 1.63, CCI20 : 165.74, Chaikin Money Flow : 0.02, MACD : 1.06, Money Flow Index : 72.68, ROC : 24.01, RSI : 64.84, STOCH (14,3) : 69.59, STOCH RSI : 0.74, UO : 57.81, Williams %R : -30.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Bailey Gregory (Buy at a value of $2 100 000), Bailey Gregory (Option Excercise at a value of $68 829), Buten Matthew (Buy at a value of $1 499 998), Buten Matthew (Option Excercise at a value of $82 810), Childs John (Buy at a value of $39 875 100), Coric Vlad (Buy at a value of $16 487 470), Coric Vlad (Option Excercise at a value of $869 494), Gentile Kimberly (Option Excercise at a value of $281 160), Gregory Hugh Bailey (Buy at a value of $2 100 000), Gregory Hugh Bailey (Option Excercise at a value of $68 829), Gregory Julia (Buy at a value of $99 992), Gregory Julia (Option Excercise at a value of $68 829), John W. Childs (Buy at a value of $79 903 100), Julia P. Gregory (Buy at a value of $99 992), Julia P. Gregory (Option Excercise at a value of $68 829), Kimberly Gentile (Option Excercise at a value of $281 160), Kishan Mehta (Option Excercise at a value of $87 860), Matthew Buten (Buy at a value of $1 499 998), Matthew Buten (Option Excercise at a value of $82 810), Mehta Kishan (Option Excercise at a value of $87 860), Michael T. Heffernan (Option Excercise at a value of $72 729), Robert J. Hugin (Option Excercise at a value of $73 406), Vlad Coric (Buy at a value of $16 487 682)